University of Calgary researchers
including Luchman, Weiss and Dr. Greg Cairncross — director of SACRI, and leader of the Terry Fox Research Institute (TFRI) «Therapeutic Targeting of
Glioblastoma research program at the university — are now working with cancer researchers Dr. Warren Mason (Princess Margaret Cancer Centre in Toronto) and Dr. Lesley Seymour (Director of the NCIC Clinical Trials Group's Investigational New Drug Program), and drug manufacturer AstraZeneca, to plan a clinical trial testing a similar, but newer, drug related to AZD8055 (called AZD2014), in combination with TMZ, in patients with g
Glioblastoma research program at the university — are now working with cancer researchers Dr. Warren Mason (Princess Margaret Cancer Centre in Toronto) and Dr. Lesley Seymour (Director of the NCIC Clinical Trials Group's Investigational New Drug Program), and drug manufacturer AstraZeneca, to plan a clinical trial testing a similar, but newer, drug related to AZD8055 (called AZD2014), in combination with TMZ, in
patients with
glioblastomaglioblastoma.
Wong was not involved in the study, but he is part of a team of researchers currently testing the device in a phase III clinical trial, which
includes more than 200
glioblastoma patients in the United States and Europe.
The NYGC and its founding member institutions are conducting additional studies involving Watson to help accelerate the discovery of potentially actionable sequence variants in various types of cancer,
including an ongoing study that involves DNA and RNA from a larger cohort of
glioblastoma patients, and a study of 200
patients with different types of cancer.